Get the Stockscreener App
0.0005
9,900%
0.00
Vaxxinity Inc stock is traded at $0.0005, with a volume of 10,387.
It is up +9,900% in the last 24 hours and down -87.90% over the past month.
See More
Previous Close:
$0.0005
Open:
$0.0005
24h Volume:
10,387
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-66.00M
P/E Ratio:
-0.000943
EPS:
-0.53
Net Cash Flow:
$-60.55M
1W Performance:
+9,900%
1M Performance:
-87.90%
6M Performance:
-95.00%
1Y Performance:
-97.29%
1-Day Range:
$0.0005
$0.04
1-Week Range:
$0.0005
$0.04
52-Week Range:
$0.0005
$0.04
Vaxxinity Inc Stock (VAXX) Company Profile
Compare VAXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.0005 | 0 | 0 | -66.00M | -60.55M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-23 | Initiated | Robert W. Baird | Outperform |
| Apr-27-22 | Initiated | Evercore ISI | In-line |
Vaxxinity Inc Stock (VAXX) Latest News
Vaxxinity Shares Plummet Amid Extreme Volatility - AD HOC NEWS
Analyzing Vaxxinity (NASDAQ:VAXX) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Tangible book value per share of Vaxxinity, Inc. – OTC:VAXX - TradingView
Hypercholesterolemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight - Barchart.com
Space Medicine Market Report 2025 | Innovative Space-Based Regenerative Medicine Aims to Enhance Human Health During Long-Duration Missions - 24matins.uk
Hypercholesterolemia Pipeline 2025: Innovative Clinical Advancements by 25+ Global Leaders – DelveInsight | Featuring companies such as Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Arr - Barchart.com
Dallas District Court Split in High-Stakes Stock Dispute - Inforney News
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Local Man Arrested on Multiple Charges, Including Drug Delivery and Bribery - Inforney News
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial - The Lancet
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
Hypercholesterolemia Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Hypercholesterolemia Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
PCSK9 Inhibitors Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Pipeline, Therapies, and Companies by DelveInsight - The Globe and Mail
🐾 Pet of the Week: Meet Benny — Forney’s Frisbee-Loving Best Friend - Inforney News
Forney ISD Issues RFP for Security Guard Services Purchasing Contract Starting July 1 2025 - Inforney News
Crime Stoppers Most Wanted- Jose Raudel Muro-Ortega - Inforney News
Forney Hospital Project Set to Transform City Landscape - Inforney News
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
New Costco in Forney to Feature $3.5M Fuel Station - Inforney News
BJ's Coming to Forney with $10 Million Dollar Build at Hwy 80 & Gateway - Inforney News
Starbucks in Kroger Set for Remodel This Summer - Inforney News
Burlington to Open a New 22,000 Sq Ft Store at Village at Gateway, Expected to Welcome Shoppers by Early 2026 - Inforney News
Forney Costco Construction Updates: Breaking Ground In April, Won't Open Before TXDOT Bridge Completes - Inforney News
Governors Small Business Summit KaufmanA Sold Out Event - Inforney News
Texas Board Of Education Approves Optional Bible Curriculum In Public Schools - Inforney News
Kaufman's Community Economic Development Award - Inforney News
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
Study: Therapeutic Parkinson's vaccine safely inhibits alpha-synuclein clumps - Parkinson's News Today
Parkinson's Prevention May Include Tetanus Vaccination - Vax-Before-Travel
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Kaufman County and TXDOT Propose New Outer LoopPublic Input Session - Inforney News
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Terrell Breaks Ground On Northspur Development - Inforney News
Vaxxinity, Inc. (VAXX) Perplexes All, Surges 44% Amidst Delisting Decision - 富途牛牛
What's Driving These Stocks Higher In After-hours? - RTTNews
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - Yahoo Finance
Vaxxinity Inc Motivates Team with Option Repricing Initiative - TipRanks
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 - Yahoo Finance
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - Yahoo Finance
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewswire
Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology - Citeline News & Insights
Vaxxinity Inc Stock (VAXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Cap:
|
Volume (24h):